Q32 BIO INC (QTTB) Stock Fundamental Analysis

NASDAQ:QTTB • US7469641051

4.5 USD
-0.08 (-1.75%)
At close: Feb 24, 2026
4.53 USD
+0.03 (+0.67%)
After Hours: 2/24/2026, 5:37:34 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall QTTB gets a fundamental rating of 1 out of 10. We evaluated QTTB against 521 industry peers in the Biotechnology industry. QTTB has a bad profitability rating. Also its financial health evaluation is rather negative. QTTB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • QTTB had negative earnings in the past year.
  • In the past year QTTB has reported a negative cash flow from operations.
  • QTTB had negative earnings in each of the past 5 years.
  • QTTB had a negative operating cash flow in each of the past 5 years.
QTTB Yearly Net Income VS EBIT VS OCF VS FCFQTTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • QTTB has a worse Return On Assets (-79.11%) than 66.41% of its industry peers.
Industry RankSector Rank
ROA -79.11%
ROE N/A
ROIC N/A
ROA(3y)-62.55%
ROA(5y)-56.34%
ROE(3y)-332.65%
ROE(5y)-224.01%
ROIC(3y)N/A
ROIC(5y)N/A
QTTB Yearly ROA, ROE, ROICQTTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • QTTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QTTB Yearly Profit, Operating, Gross MarginsQTTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • QTTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for QTTB has been increased compared to 1 year ago.
  • Compared to 5 years ago, QTTB has less shares outstanding
  • Compared to 1 year ago, QTTB has a worse debt to assets ratio.
QTTB Yearly Shares OutstandingQTTB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QTTB Yearly Total Debt VS Total AssetsQTTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -6.86, we must say that QTTB is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of QTTB (-6.86) is worse than 64.68% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.86
ROIC/WACCN/A
WACC8.67%
QTTB Yearly LT Debt VS Equity VS FCFQTTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • QTTB has a Current Ratio of 5.06. This indicates that QTTB is financially healthy and has no problem in meeting its short term obligations.
  • QTTB's Current ratio of 5.06 is in line compared to the rest of the industry. QTTB outperforms 56.24% of its industry peers.
  • A Quick Ratio of 5.06 indicates that QTTB has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.06, QTTB is in line with its industry, outperforming 57.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.06
Quick Ratio 5.06
QTTB Yearly Current Assets VS Current LiabilitesQTTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • QTTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.96%, which is quite impressive.
  • QTTB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)84.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • QTTB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.32% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.2%
EPS Next 2Y36.4%
EPS Next 3Y20.32%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QTTB Yearly Revenue VS EstimatesQTTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 10M 20M 30M
QTTB Yearly EPS VS EstimatesQTTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for QTTB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QTTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTTB Price Earnings VS Forward Price EarningsQTTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTTB Per share dataQTTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4

4.3 Compensation for Growth

  • QTTB's earnings are expected to grow with 20.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.4%
EPS Next 3Y20.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • QTTB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

Q32 BIO INC

NASDAQ:QTTB (2/24/2026, 5:37:34 PM)

After market: 4.53 +0.03 (+0.67%)

4.5

-0.08 (-1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)05-06
Inst Owners46.11%
Inst Owner Change-4.8%
Ins Owners0.58%
Ins Owner Change-4.45%
Market Cap55.35M
Revenue(TTM)N/A
Net Income(TTM)-52.30M
Analysts82.5
Price Target11.56 (156.89%)
Short Float %3.33%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.12%
Min EPS beat(2)21.97%
Max EPS beat(2)28.26%
EPS beat(4)3
Avg EPS beat(4)18.24%
Min EPS beat(4)-1.95%
Max EPS beat(4)28.26%
EPS beat(8)4
Avg EPS beat(8)-64.5%
EPS beat(12)5
Avg EPS beat(12)-47.8%
EPS beat(16)9
Avg EPS beat(16)-31.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)15.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-4.38
FCFYN/A
OCF(TTM)-4.38
OCFYN/A
SpS0
BVpS-0.99
TBVpS-0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.55%
ROA(5y)-56.34%
ROE(3y)-332.65%
ROE(5y)-224.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.06
Quick Ratio 5.06
Altman-Z -6.86
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)51.62%
Cap/Depr(5y)46.08%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.9%
EPS Next Y85.2%
EPS Next 2Y36.4%
EPS Next 3Y20.32%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-133.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.12%
OCF growth 3YN/A
OCF growth 5YN/A

Q32 BIO INC / QTTB FAQ

Can you provide the ChartMill fundamental rating for Q32 BIO INC?

ChartMill assigns a fundamental rating of 1 / 10 to QTTB.


What is the valuation status for QTTB stock?

ChartMill assigns a valuation rating of 1 / 10 to Q32 BIO INC (QTTB). This can be considered as Overvalued.


How profitable is Q32 BIO INC (QTTB) stock?

Q32 BIO INC (QTTB) has a profitability rating of 0 / 10.


What is the financial health of Q32 BIO INC (QTTB) stock?

The financial health rating of Q32 BIO INC (QTTB) is 3 / 10.